Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BullsEye Study XL of vedolizumab response biomarkers in Crohn's disease
NL-OMON54895Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of vedolizumab in Crohn's disease and inflammatory bowel disease (IBD), sponsored by University Medical Center Utrecht. Primary endpoint: Primary biomarker identification. Started Dec 2021; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON54895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54895.